The M&A Pool Set to Accelerate Biotech Innovation
Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Pathfinders in Biopharma?
This episode is 13 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on April 3, 2024.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.